A Phase I Open-label, 2-period Study to Evaluate the Influence of Multiple Oral Doses of Rifampin on the Single Dose Pharmacokinetics of Romidepsin in Subjects With Advanced Cancer.
Phase of Trial: Phase I
Latest Information Update: 04 Jun 2015
At a glance
- Drugs Romidepsin (Primary) ; Rifampicin
- Indications Bacterial infections; Cancer
- Focus Pharmacokinetics
- Sponsors Celgene Corporation
- 14 Jun 2012 Actual patient number 14 added as reported by ClinicalTrials.gov.
- 14 Jun 2012 Actual end date (1 Mar 2012) added as reported by ClinicalTrials.gov.
- 14 Jun 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.